18 and older, female only, with COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
COVID-19 Testing and Vaccine KnowledgePrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Nine multiple-choice items developed by study team and corresponding to intervention content, which regarding COVID-19 transmission, risk, mitigation, vaccine risk, and testing in a pandemic environment .
The sum of scores on all 9 items has a possible total score ranges from 0 (minimum) to 9 (maximum), a higher score represents a higher level of COVID-19 testing and vaccine knowledge (i.e., better outcome).
Pre-intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.58
± 1.36
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.98
± 1.36
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.85
± 1.39
COVID-19 Mistrust ScorePrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
General COVID-19 Mistrust Scale (PMID: 33196555) Adopted 4-items COVID-19 Mistrust Scale, which focus on public information advanced by the government and public health care providers.
Each item was on 5-point Likert Scare range from 1 (strongly disagree) to 5 (strongly agree).
A mean score of 4 items represent participants' mistrust level towards government and public health care providers, which ranges from 1 (minimum) to 5 (maximum).
A higher score means a higher mistrust score (i.e., worse outcome).
Pre-intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.25
± 1.21
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.09
± 1.16
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
3.21
± 1.08
COVID-19 Testing Accessibility - Ease of AccessPrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Self-reported perceived accessibility of COVID-19 testing. A 5-point Likert scale item ranges from 1 (strongly disagree) to 5 (strongly agree).
A higher score represent participants' higher level of perceived accessibility (i.e., a better outcome).
Pre-Intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
4.36
± 1.03
1-month
Group
Value
95% CI
COVID-19 mHealth Intervention
4.51
± 0.89
12-month
Group
Value
95% CI
COVID-19 mHealth Intervention
4.49
± 0.96
COVID-19 Testing Accessibility - Confidence to LocatePrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Self-reported confidence level of locating the place to get COVID-19 testing. A 5-point Likert scale item ranges from 1 (strongly disagree) to 5 (strongly agree).
A higher score represent participants' higher level of confidence (i.e., a better outcome).
Pre-Intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
4.42
± 1.05
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
4.54
± 0.95
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
4.49
± 0.96
COVID-19 Testing Accessibility - Free AccessPrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Percentage of participants' aware the government program that offers free tests through the mail.
Pre-Intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
209
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
221
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
195
Ever Had COVID-19 TestingPrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Count number of participants who indicated they ever had COVID-19 testing.
Pre-Intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
264
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
253
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
229
Ever Received COVID-19 VaccinePrimary· Pre-Intervention assessment measured at baseline, Post-intervention assessment measured at 1-month and 12-month follow-ups.
Count number of participants who indicated they ever had COVID-19 vaccine.
Pre-Intervention assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
191
1-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
182
12-month assessment
Group
Value
95% CI
COVID-19 mHealth Intervention
165
Sponsor's own description
The objective of this research is to use a localized mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults
· active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study
· recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI)
· NA
· active not recruiting
NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival
· recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive
· NA
· not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice
· NA
· enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease.
· NA
· not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives
· NA
· recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582746.